Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Palliative care with cervical intrathecal infusion and external pump for a late-stage cancer patient with refractory pain

Palliative care with cervical intrathecal infusion and external pump for a late-stage cancer... AbstractRationale:Intrathecal therapy, with a low complication rate, has become an alternative to standard pain management for treatment of neuropathic cancer pain.Patient concerns:Here, we reported a late-stage cancer patient with intractable neuropathic pain in his right neck, shoulder, and upper limb.Diagnoses:The pain started 2 years ago when the patient was diagnosed as squamous cell carcinoma with metastasis to right supraclavicular lymph nodes.Interventions:Cervical intrathecal infusion of morphine and bupivacaine with patient control analgesia by external pump was performed. The intrathecal catheter was located at the level of C6 vertebra. The initial concentration of bupivacaine and morphine were both 1 mg/mL with infusion rate of 0.3 mL/h and bolus of 0.3 mL. Subsequently, the concentrations increased to 2 mg/mL (bupivacaine) and 1.33 mg/mL (morphine), with infusion rate to 0.6 mL/h and bolus to 0.5 ml.Outcomes:The pain intensity decreased from numerical rating scale 6 to 7 to 2 to 3 at rest, and from 10 to 5 to 6 of breakthrough pain.Lessons:In conclusion, cervical intrathecal infusion requires low concentration but high doses of bupivacaine and morphine, which is safe and effective in cancer patients with refractory pain and short life expectancy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Medicine Wolters Kluwer Health

Palliative care with cervical intrathecal infusion and external pump for a late-stage cancer patient with refractory pain

Medicine , Volume 97 (4) – Jan 1, 2018

Loading next page...
 
/lp/wolters_kluwer/palliative-care-with-cervical-intrathecal-infusion-and-external-pump-nQs06DX403

References (37)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.
ISSN
0025-7974
eISSN
1536-5964
DOI
10.1097/MD.0000000000009714
pmid
29369202
Publisher site
See Article on Publisher Site

Abstract

AbstractRationale:Intrathecal therapy, with a low complication rate, has become an alternative to standard pain management for treatment of neuropathic cancer pain.Patient concerns:Here, we reported a late-stage cancer patient with intractable neuropathic pain in his right neck, shoulder, and upper limb.Diagnoses:The pain started 2 years ago when the patient was diagnosed as squamous cell carcinoma with metastasis to right supraclavicular lymph nodes.Interventions:Cervical intrathecal infusion of morphine and bupivacaine with patient control analgesia by external pump was performed. The intrathecal catheter was located at the level of C6 vertebra. The initial concentration of bupivacaine and morphine were both 1 mg/mL with infusion rate of 0.3 mL/h and bolus of 0.3 mL. Subsequently, the concentrations increased to 2 mg/mL (bupivacaine) and 1.33 mg/mL (morphine), with infusion rate to 0.6 mL/h and bolus to 0.5 ml.Outcomes:The pain intensity decreased from numerical rating scale 6 to 7 to 2 to 3 at rest, and from 10 to 5 to 6 of breakthrough pain.Lessons:In conclusion, cervical intrathecal infusion requires low concentration but high doses of bupivacaine and morphine, which is safe and effective in cancer patients with refractory pain and short life expectancy.

Journal

MedicineWolters Kluwer Health

Published: Jan 1, 2018

There are no references for this article.